Principal investigator(s)
Martin Klein
Amsterdam, Netherlands
, Jaap Reijneveld
VU University Medical Center / Amsterdam Medical Center
Amsterdam, Netherlands
Project coordinator(s)
Ivan Caramanna
Amsterdam, Netherlands

Project summary

In glioma patients the correlation of self-rated cognitive abilities with HRQOL was never compared with that of objective abilities, nor has the concomitant influence of tumor- and treatment-related and demographic variables ever been taken into consideration. Furthermore, studies on the impact of cognitive functioning on differences between HRQOL-ratings by patients and proxies show contradictory results. On these grounds, given the significant risk of cognitive impairment in brain tumor patients, this study aims at clarifying the impact of self-awareness of cognitive deficits and objective cognitive deficits on self-reported HRQOL and to evaluate if such an impact is a by-product of tumor- and treatment-related variables. Perceived and objective deficits are expected to affect HRQOL differently.


Two research published, one under revision.

Future plans

An almost ready manuscript is currently being updated and another is in due progress.

All research submitted to peer-review by September

For patients

It is common for people having a brain tumour to struggle to concentrate or pay attention as well as not to behave anymore as before the tumour. The health-related Quality of Life score measures how physically and mentally someone is feeling during treatment. We want to know if  what is happening to them and being aware of it could influence the way patients report their health-related quality of life.


Caramanna I, Bottomley A, Drijver AJ, Twisk J, van den Bent M, Idbaih A, Wick W, Pe M, Klein M, Reijneveld JC; EORTC Quality of Life Group and Brain Tumour Group. Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials. Eur J Cancer. 2021 Feb;144:162-168. doi: 10.1016/j.ejca.2020.10.040. Epub 2020 Dec 22. PMID: 33348088.

  • (waiting for approval and hopefully published by the meeting) Neurocognitive impairment and patient–proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients.